Demuynck H, Pettengell R, de Campos E, Dexter T M, Testa N G
CRC Department of Experimental Haematology, Paterson Institute for Cancer Research, Manchester, U.K.
Eur J Cancer. 1992;28(2-3):381-6. doi: 10.1016/s0959-8049(05)80058-9.
After treatment of patients with intermediate or high grade non-Hodgkin lymphoma with chemotherapy plus G-CSF the numbers of haemopoietic progenitor cells in the circulation increased to a mean of 226-fold for mixed CFC (Mix-CFC), 278-fold for GM-CFC and 29-fold for erythroid burst forming unit (BFU-E). The mean increase was modest (7-12-fold) for patients treated with chemotherapy alone. Peripheral blood mononuclear cells harvested at the time of the peak in the numbers of progenitors, or 2-4 days before the peak, seeded onto irradiated marrow stroma in vitro, repopulated the stroma and generated active haemopoiesis at least as effectively as bone marrow cells on a cell per cell basis. This is in contrast to the poor repopulating capacity of pretreatment blood. The results indicate that not only the progenitor cells, but also the repopulating stem cells migrated into the blood after chemotherapy plus G-CSF in sufficient numbers to allow harvesting and successful grafting without the possible complication of late haemopoietic failure.
用化疗加粒细胞集落刺激因子(G-CSF)治疗中、高度非霍奇金淋巴瘤患者后,循环中的造血祖细胞数量平均增加:混合集落形成细胞(Mix-CFC)增加226倍,粒-巨噬细胞集落形成细胞(GM-CFC)增加278倍,红系爆式集落形成单位(BFU-E)增加29倍。单独接受化疗的患者平均增加幅度较小(7-12倍)。在祖细胞数量达到峰值时或峰值前2-4天采集的外周血单个核细胞,接种到经照射的骨髓基质上进行体外培养,其在基质上的再增殖能力以及产生活跃造血的能力,在单个细胞水平上至少与骨髓细胞一样有效。这与预处理血液的较差再增殖能力形成对比。结果表明,化疗加G-CSF后,不仅祖细胞,而且再增殖干细胞也大量迁移到血液中,从而能够进行采集并成功移植,且不会出现晚期造血功能衰竭这种可能的并发症。